Fuller & Thaler Asset Management Inc. Sells 127,841 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Fuller & Thaler Asset Management Inc. decreased its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 10.1% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,132,926 shares of the company's stock after selling 127,841 shares during the period. Fuller & Thaler Asset Management Inc. owned approximately 2.36% of Amphastar Pharmaceuticals worth $42,066,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its stake in shares of Amphastar Pharmaceuticals by 43.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after purchasing an additional 348 shares during the period. Huntington National Bank raised its stake in shares of Amphastar Pharmaceuticals by 36.9% during the fourth quarter. Huntington National Bank now owns 1,340 shares of the company's stock valued at $50,000 after purchasing an additional 361 shares during the period. Bank of Montreal Can raised its stake in shares of Amphastar Pharmaceuticals by 4.6% during the fourth quarter. Bank of Montreal Can now owns 8,215 shares of the company's stock valued at $305,000 after purchasing an additional 361 shares during the period. TD Private Client Wealth LLC raised its stake in shares of Amphastar Pharmaceuticals by 22.7% during the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock valued at $78,000 after purchasing an additional 388 shares during the period. Finally, Smartleaf Asset Management LLC raised its stake in shares of Amphastar Pharmaceuticals by 222.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after purchasing an additional 493 shares during the period. Hedge funds and other institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Trading Up 0.3 %

Amphastar Pharmaceuticals stock traded up $0.07 during midday trading on Tuesday, reaching $24.48. The stock had a trading volume of 70,442 shares, compared to its average volume of 463,723. The firm's fifty day simple moving average is $26.91 and its two-hundred day simple moving average is $36.27. Amphastar Pharmaceuticals, Inc. has a twelve month low of $22.64 and a twelve month high of $53.96. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of 8.16, a PEG ratio of 2.19 and a beta of 0.79.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the firm's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 27.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AMPH. Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Piper Sandler lowered their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Friday, March 21st.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.